DPYSL2 and neoplasm: Notably, a significant difference in CRMP2 levels in tumor loci between CRC and CRC-DM subjects was identified (p < 0.0001, Table 1): 17 (27.9%) and 44 (72.1%) CRC subjects had low and high CRMP2 staining intensity, respectively, while the corresponding prevalence of low and high CRMP2 levels in CRC-DM patients was 36 (78.3%) and 10 (21.7%).